Aldeyra’s ADX-2191 Receives FDA’s Fast Track Designation to Prevent Proliferative Vitreoretinopathy

 Aldeyra’s ADX-2191 Receives FDA’s Fast Track Designation to Prevent Proliferative Vitreoretinopathy

Aldeyra’s ADX-2191 Receives FDA’s Fast Track Designation to Prevent Proliferative Vitreoretinopathy

Shots:

  • The US FDA has granted FT designation to ADX-2191 for the prevention of proliferative vitreoretinopathy and provides it eligibility for Priority Review and rolling NDA submission
  • The FDA’s FT designation facilitates the development and expedites the review of drugs that treat serious conditions, potentially accelerating patient access to new therapies
  • ADX-2191 is an intravitreal formulation of methotrexate and has received FDA’s ODD for preventing PVR with its expected onset of P-III GUARD Trial in Q4’19. The study will evaluate recurrence rates of PVR-related retinal detachment in patients treated with ADX-2191 or SoC following surgical repair of retinal detachment

Click here to­ read full press release/ article | Ref: Aldeyra | Image: Aldeyra

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post